000156575 001__ 156575
000156575 005__ 20251017144604.0
000156575 0247_ $$2doi$$a10.2217/nnm-2019-0371
000156575 0248_ $$2sideral$$a118681
000156575 037__ $$aART-2020-118681
000156575 041__ $$aeng
000156575 100__ $$aLacoma, Alicia
000156575 245__ $$aNovel intracellular antibiotic delivery system against Staphylococcus aureus: Cloxacillin-loaded poly(d, l-lactide-co-glycolide) acid nanoparticles
000156575 260__ $$c2020
000156575 5060_ $$aAccess copy available to the general public$$fUnrestricted
000156575 5203_ $$aAim: First, to compare in vitro minimum inhibitory concentrations (MIC) of free cloxacillin and cloxacillin-containing nanoparticles (NP) against methicillin-susceptible (MSSA) and resistant Staphylococcus aureus (MRSA) and second, to assess NP antimicrobial activity against intracellular S. aureus. Methods: Poly(d, l-lactide-co-glycolide) acid (PLGA)-NP were loaded with cloxacillin and physico-chemically characterized. MICs were determined for reference strains Newman-(MSSA) and USA300-(MRSA). Murine alveolar macrophages were infected, and bacterial intracellular survival was assessed after incubating with free-cloxacillin or PLGA-cloxacillin-NP. Results & conclusion: For both isolates, MICs for antibiotic-loaded-NP were lower than those obtained with free cloxacillin, indicating that the drug encapsulation improves antimicrobial activity. A sustained antibiotic release was demonstrated when using the PLGA-cloxacillin-NP. When considering the lowest concentrations, the use of drug-loaded NP enabled a higher reduction of intracellular bacterial load.
000156575 536__ $$9info:eu-repo/grantAgreement/EUR/ERC-2013-CoG-614715-NANOHEDONISM$$9info:eu-repo/grantAgreement/ES/ISCIII/FEDER/PI17-01139$$9info:eu-repo/grantAgreement/ES/MICINN/CTQ2017-84473-R
000156575 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000156575 590__ $$a5.307$$b2020
000156575 591__ $$aBIOTECHNOLOGY & APPLIED MICROBIOLOGY$$b30 / 158 = 0.19$$c2020$$dQ1$$eT1
000156575 591__ $$aNANOSCIENCE & NANOTECHNOLOGY$$b46 / 106 = 0.434$$c2020$$dQ2$$eT2
000156575 592__ $$a0.946$$b2020
000156575 593__ $$aBioengineering$$c2020$$dQ1
000156575 593__ $$aBiomedical Engineering$$c2020$$dQ1
000156575 593__ $$aNanoscience and Nanotechnology$$c2020$$dQ1
000156575 593__ $$aMaterials Science (miscellaneous)$$c2020$$dQ1
000156575 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000156575 593__ $$aDevelopment$$c2020$$dQ1
000156575 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000156575 700__ $$0(orcid)0000-0002-4678-7465$$aUsón, Laura$$uUniversidad de Zaragoza
000156575 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, Gracia$$uUniversidad de Zaragoza
000156575 700__ $$0(orcid)0000-0002-6873-5244$$aSebastián, Víctor$$uUniversidad de Zaragoza
000156575 700__ $$aGarcia-Garcia, Esther
000156575 700__ $$aMuriel-Moreno, Beatriz
000156575 700__ $$aDomínguez, José
000156575 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, Manuel$$uUniversidad de Zaragoza
000156575 700__ $$aPrat, Cristina
000156575 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000156575 773__ $$g15, 12 (2020), 1189-1203$$pNanomedicine$$tNanomedicine$$x1743-5889
000156575 8564_ $$s9881300$$uhttps://zaguan.unizar.es/record/156575/files/texto_completo.pdf$$yVersión publicada
000156575 8564_ $$s1200034$$uhttps://zaguan.unizar.es/record/156575/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000156575 909CO $$ooai:zaguan.unizar.es:156575$$particulos$$pdriver
000156575 951__ $$a2025-10-17-14:14:51
000156575 980__ $$aARTICLE